Axikin Pharmaceuticals
Axikin

July 10, 2013 - Axikin Pharmaceuticals receives No Objection Letter for Phase 2 study of AXP1275 in Canada. — On the heels of a successful Phase 1 study for AXP1275, Axikin Pharmaceuticals submitted a Clinical Trial Application for AXP1275 on June 10, 2013, for which a No Objection Letter was received. The Phase 2 study will be a 3-centered study to investigate the efficacy of AXP1275.... Read On...

July 20, 2012 - Axikin Pharmaceuticals submits IND for AXP1275.
Axikin Pharmaceuticals, Inc. submits an IND application to the FDA for Phase 1 study of AXP1275. The proposed Phase 1 study will investigate the safety and tolerability of AXP1275 in healthy volunteers and represents a novel class of orally-available allosteric modulators against the CCR3 chemokine receptor.... Read On...

February 22nd, 2010 - Proteros and Axikin reach significant milestones with integrated drug discovery project. — In January 2010, only nine months after having set up the collaboration, rapid progress has been made in discovering and characterizing distinct chemical entities towards a novel therapeutic target for chronic obstructive pulmonary disease (COPD)... Read On...

January 22, 2009 - Axikin Pharmaceuticals Spins Out of Actimis
Axikin Pharmaceuticals, Inc., a startup company dedicated to developing and commercializing small molecule therapeutics for respiratory and inflammatory diseases, today announced a $3 million private placement of its Series A stock. The financing was led by Sanderling Ventures... Read On...

 

 

 

 

 

 

 

 

 

 

Media Contact
Karen Sparks

Mentus
858-455-5500 x275
858-458-1890
karen@mentus.com

Company Contact
Kevin Bacon, Ph.D.
4940 Carroll Canyon Road
Suite 100
San Diego, CA 92121
Phone: (858) 458-1890
kbacon@axikin.com

 

driven by rightturn